Following Sanofi’s (SFY) FDA setback today, the guys turn to the webcam to ask a nutrition expert about the viability of a miracle weight-loss drug.
Dr. Kelly Brownell, co-founder and director of Yale’s Rudd Center for Food Policy & Obesity, says the hope will go on because the market for such a drug is “tremendous” with two-third of Americans overweight and many of them desperate for a miracle pill. But Brownell doesn’t see anything in the pipeline. He thinks the real hope for the obesity crisis lies in prevention, and the burden then moves to the food industry, as well as the individual. So while Big Pharma will continue to develop the perfect weight loss drug because of the huge market it would tap, the real answer may have to come from elsewhere, Brownell says.
Stacey Briere Gilbert Is Chief Options Strategist For Susquehanna Financial Group, LLLP
Gilbert Is Head Of Market Intelligence Research For Susquehanna Financial Group, LLLP
Gilbert Does Not Cover Individual Securities But Does Recommend Trading Strategies; An Affiliate Of Susquehanna Financial Group, LLLP Is An Options Specialist In Certain Of The Stocks Discussed By Gilbert; An Affiliate Of Susquehanna Financial Group, LLLP Is A Market Maker In Certain Of The Stocks Discussed By Gilbert; Gilbert Owns (TIE); Susquehanna Financial Group, LLLP And Affiliates Own More Than 1% Of The Shares In (CAL); Bolling Owns Gold, (ICE), (NMX); Najarian Owns (STX), (MS), Is Short (AMR) and (CAL); GE Is The Parent Company Of CNBC
Got something to say?! Send us an e-mail at firstname.lastname@example.org and your comment might be posted on the web! Prefer to keep it between us. You can still send questions and comments to email@example.com.